Accelmed

Accelmed, established in 2009, is a private equity firm headquartered in Miami, Florida, with additional offices in New Jersey and Israel. The company specializes in investing in mature, middle-market HealthTech companies, focusing on medical devices, diagnostics, digital health, and technology-enabled services. Accelmed targets private and public companies based in the United States, Canada, Israel, and Europe, with sales ranging from $10 million to $80 million. The firm takes both minority and majority stakes, typically investing between $10 million and $100 million per company. Accelmed works closely with management teams to accelerate growth, improve operations, and drive successful exits.

Uri Geiger

Founder and Managing Partner

Camilo Rico

Vice President

Stephen Rubin

General Partner

Camilo Rico

Vice President

39 past transactions

GT Medical Technologies

Series D in 2025
GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, dedicated to improving the lives of patients with brain tumors. Founded in 2017, the company has developed an innovative treatment approach through its flagship product, GammaTile, which combines a biocompatible, conformable collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a bioresorbable solution that enhances treatment efficacy. GammaTile is protected by multiple patents and has the potential to benefit a significant patient population, with an estimated 176,000 patients diagnosed annually in the United States. To date, clinical trials at Barrow Neurological Institute have demonstrated promising outcomes, with significant clinical improvements observed in patients treated with this novel device.

Bioventus - Advanced Rehabilitation Business

Acquisition in 2024
Bioventus - Advanced Rehabilitation Business is a unit of Bioventus that provides rehabilitation and healthcare services to patients.

Revamp Medical

Series A in 2023
Revamp Medical, founded in 2016, is dedicated to addressing the critical unmet needs of patients suffering from acute heart failure. With over one million annual admissions in the United States and associated costs exceeding $65 billion, the company aims to provide an innovative solution through its patented temporary catheter, Doraya™. This device regulates vascular hemodynamics, particularly for patients experiencing diuretic resistance, by managing preload and reducing central venous pressure. This functionality enhances diuretic efficacy and facilitates progressive decongestion, thereby allowing cardiologists to effectively manage key hemodynamic parameters. Revamp Medical is supported by a skilled team with extensive experience in the medical technology sector, positioning the company to make a significant impact in the treatment of acute heart failure.

Minerva Surgical

Post in 2022
Minerva Surgical Inc. is a medical technology company based in Redwood City, California, dedicated to women's healthcare. Founded in 2008, the company specializes in developing, manufacturing, and commercializing minimally invasive solutions for uterine health. Its flagship product, the Minerva Endometrial Ablation System, is designed to treat abnormal uterine bleeding, a common issue affecting many women. Minerva Surgical offers a comprehensive range of alternatives to hysterectomy, aiming to address the underlying causes of abnormal uterine bleeding while preserving the uterus. These solutions are applicable in various medical environments and seek to overcome the limitations of traditional treatment methods, providing women with effective and less invasive options for their healthcare needs.

MedMinder Systems

Debt Financing in 2022
MedMinder Systems, Inc. is a company that specializes in developing innovative solutions for medication management and adherence support. Founded in 2007 and headquartered in Needham, Massachusetts, the company offers a range of products including automatic pill dispensers that remind users of their medication schedules through visual and auditory alerts, as well as notifications sent to caregivers and pharmacists. MedMinder's offerings include various types of pill dispensers, locked dispensers, medical alert products, and pre-filled medication trays. The company serves a diverse customer base across several states, including Massachusetts, New York, Florida, and others. Through its services, MedMinder aims to simplify the process of taking medications, thereby improving adherence and enhancing patient care.

MedMinder Systems

Venture Round in 2022
MedMinder Systems, Inc. is a company that specializes in developing innovative solutions for medication management and adherence support. Founded in 2007 and headquartered in Needham, Massachusetts, the company offers a range of products including automatic pill dispensers that remind users of their medication schedules through visual and auditory alerts, as well as notifications sent to caregivers and pharmacists. MedMinder's offerings include various types of pill dispensers, locked dispensers, medical alert products, and pre-filled medication trays. The company serves a diverse customer base across several states, including Massachusetts, New York, Florida, and others. Through its services, MedMinder aims to simplify the process of taking medications, thereby improving adherence and enhancing patient care.

Veranex

Private Equity Round in 2022
Veranex is a global service provider that specializes in the medical technology sector, offering comprehensive, technology-enabled solutions from concept to commercialization. The company focuses exclusively on various areas within medical technology, including medical devices, diagnostics, companion diagnostics, digital health, and drug delivery. Veranex provides a wide range of services, such as design and engineering, regulatory support, clinical trials, and market access, enabling clients to streamline their development processes. By addressing the entire clinical trial journey, Veranex helps clients accelerate their time to market, enhance market viability, manage development costs, and reduce associated risks.

Click Therapeutics

Series B in 2021
Click Therapeutics, Inc. is a New York-based company that specializes in the engineering, validation, development, and commercialization of digital therapeutics aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012, Click Therapeutics focuses on creating software-based medical treatments for various conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, and chronic pain. Its innovative Digital Therapeutics™ can be utilized independently or alongside traditional biomedical treatments, enhancing patient engagement and treatment outcomes. The company's Clickometrics® adaptive data science platform personalizes user experiences to optimize results. Notably, Click's smoking cessation program has successfully launched nationwide, and its leading prescription program is currently undergoing a phase III FDA registration trial for treating Major Depressive Disorder in adults.

Keystone Dental

Venture Round in 2021
Keystone Dental, Inc. is an oral healthcare company based in Burlington, Massachusetts, founded in 2006. It specializes in the manufacture and commercialization of dental implants, biomaterials, and planning software for dental professionals. The company's biomaterials portfolio includes a variety of products such as extracellular, resorbable, and non-resorbable membranes, along with advanced bone grafting solutions like demineralized bone matrix and osteoinductive dental bone graft substitutes. Keystone Dental also offers mineralized allograft particulates and bioactive synthetic bone grafts, among other products. The company aims to establish a trusted global brand within the dental community, focusing on enhancing patient care and quality of life. Additionally, Keystone Dental has formed a strategic alliance with DDS Lab to strengthen its market presence.

TailorMed

Venture Round in 2021
TailorMed Medical Ltd., established in 2017 and based in Tel Aviv, Israel, specializes in health IT solutions. The company develops and provides financial navigation technology and systems, designed to streamline and automate financial processes for both patients and healthcare providers. Their offerings include TailorMed Financial Navigation, a platform to manage and automate financial processes; TailorMed Financial Insights, an analytics and reporting dashboard to track and measure key performance indicators; and TailorMed Pharmacy, a platform to simplify drug ordering, tracking, and billing based on patient treatment regimens.

Memic Innovative Surgery

Series D in 2021
Memic Innovative Surgery develops and delivers robotic surgical solutions designed to enable otherwise infeasible surgical procedures. Its first offering facilitates a variety of robotic gynecological procedures via a vaginal approach, expanding the feasibility of vaginal surgery to the vast majority of cases. Its robotic technology consists of miniature and humanoid-shaped articulated arms that mimic human dexterity while surpassing human flexibility. The robotic arms are controllable via various proprietary control consoles to maintain natural control of the arms, allowing surgeons to operate precisely in tight anatomical spaces with decreased risk to nearby organs and tissue.

MedMinder Systems

Private Equity Round in 2021
MedMinder Systems, Inc. is a company that specializes in developing innovative solutions for medication management and adherence support. Founded in 2007 and headquartered in Needham, Massachusetts, the company offers a range of products including automatic pill dispensers that remind users of their medication schedules through visual and auditory alerts, as well as notifications sent to caregivers and pharmacists. MedMinder's offerings include various types of pill dispensers, locked dispensers, medical alert products, and pre-filled medication trays. The company serves a diverse customer base across several states, including Massachusetts, New York, Florida, and others. Through its services, MedMinder aims to simplify the process of taking medications, thereby improving adherence and enhancing patient care.

NeuroPace

Private Equity Round in 2020
NeuroPace, Inc. is a commercial-stage medical device company based in Mountain View, California, that specializes in the treatment of neurological disorders through innovative implantable devices. Founded in 1997, NeuroPace has developed the Responsive Neurostimulator (RNS) System, which is designed to monitor and respond to brain activity in patients with medically refractory partial epilepsy. The RNS System includes a small implantable neurostimulator connected to leads placed in seizure onset areas, delivering targeted electrical pulses to help reduce or eliminate seizures. NeuroPace primarily generates revenue from the sales of its RNS System to hospitals and specialized medical facilities that perform the implantation procedures.

TearLab

Acquisition in 2020
TearLab Corporation is an in-vitro diagnostic company based in Escondido, California, specializing in the development and marketing of innovative tear testing technologies for the diagnosis of dry eye disease. The company’s flagship product, the TearLab Osmolarity System, is a proprietary platform that allows eye care practitioners to measure tear film osmolarity and identify sensitive biomarkers using only nanoliters of tear film at the point-of-care. This system includes a disposable microfluidic chip, a hand-held device known as the TearLab Pen for sample collection, and the TearLab Reader, a desktop unit that provides quantitative results. Founded in 1996, TearLab aims to enhance the standard of care in ophthalmology through objective and precise testing methodologies.

BioProtect

Series D in 2020
BioProtect Ltd. is an international medical device startup founded in 2004 and headquartered in Israel, with subsidiaries in Germany and the United States. The company specializes in the development and commercialization of biodegradable balloon spacers designed to protect normal tissue during radiation therapy for cancer. Its flagship product, the ProSpace balloon spacer, has received CE marking and demonstrates superior efficacy and safety in safeguarding the rectum during prostate cancer radiation therapy. By creating a temporary separation between the rectum and targeted tissues, BioProtect's technology significantly reduces the risk of serious and chronic side effects associated with radiation treatment while enhancing tumor control. Additionally, the company's platform of biodegradable implantable balloons addresses a variety of unmet clinical needs in the growing radiotherapy spacers market.

Diagnostic Robotics

Series A in 2019
Diagnostic Robotics develops an artificial intelligence system for healthcare insurers, providers, and patients. Founded in 2017 and based in Tel Aviv, Israel, the company creates predictive analytics models to address clinical and financial challenges in healthcare. These models aim to optimize clinical program performance, increase return on investment, and enable more effective care at lower costs by allowing for informed decisions and proactive interventions.

EndoGastric Solutions

Series I in 2019
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

STRATA Skin Sciences

Post in 2018
STRATA Skin Sciences, Inc. is a medical technology company focused on developing, commercializing, and marketing products for the treatment of dermatologic conditions. Founded in 1989 and based in Horsham, Pennsylvania, the company operates primarily in two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its key products include the XTRAC excimer laser and VTRAC lamp systems, which are used to treat a variety of skin disorders such as psoriasis, vitiligo, atopic dermatitis, and eczema. Additionally, STRATA offers the MelaFind system, designed to aid in the identification and management of melanoma skin cancer. The company distributes its products both domestically, directly to physicians, and internationally through distributors.

Cogentix Medical

Post in 2016
Cogentix Medical, Inc. is a medical device company based in Minnetonka, Minnesota, specializing in the design, development, manufacturing, and marketing of advanced fiberoptic and video endoscopy products under the PrimeSight brand. The company offers a variety of endoscopes, including cystoscopes and bronchoscopes, along with the EndoSheath Protective Barrier, a sterile, single-use microbial barrier for flexible endoscopes. Cogentix Medical is also known for its Urgent PC System, which provides percutaneous tibial nerve stimulation for the treatment of overactive bladder, and Macroplastique, an injectable urethral bulking agent for adult female stress urinary incontinence. In addition to these products, the company distributes wound care products in the Netherlands and the United Kingdom. Cogentix Medical operates through a direct sales force and a network of distributors, having been formed in 2015 through the merger of Uroplasty and Vision-Sciences.

SoniVie

Venture Round in 2015
SoniVie is a medical device company focused on developing innovative solutions for the treatment of pulmonary hypertension. The company has created a minimally invasive denervation device that is designed to be inserted into the pulmonary artery through a catheterization procedure. This advanced technology selectively targets and damages the nerves associated with pulmonary hypertension, while preserving the integrity of the vessel walls and surrounding tissues. By enabling physicians to perform denervation procedures with greater precision, SoniVie aims to improve treatment options and outcomes for patients suffering from this serious condition.

Eximo

Series A in 2015
Eximo Medical Ltd. is an innovative company based in Modi'in-Maccabim-Re'ut, Israel, specializing in hybrid catheter technology for tissue resection in vascular and gastrointestinal endoluminal applications. Founded in 2012, Eximo has developed a proprietary single-use hybrid catheter known as CatHI, which integrates optical fibers that emit short laser pulses and a blunt mechanical knife. This advanced technology aims to enhance safety and performance during medical procedures, particularly in atherectomy, by minimizing the risk of vessel perforation. As of October 2019, Eximo Medical operates as a subsidiary of AngioDynamics, Inc.

Digma Medical

Series A in 2015
Digma Medical is a clinical stage medical device company focused on innovative treatments for Type-2 Diabetes and related metabolic disorders, including NASH. Founded in 2013, the company is developing the DiaGone™, a disposable endoscopic device that employs advanced laser technology to target the duodenum, the first section of the small intestine. This device is designed to address insulin resistance, the core issue in these diseases. The Duodenal Glycemic Control™ procedure, which lasts approximately 30 minutes, allows gastroenterologists to utilize the DiaGone™ to enhance the body's natural ability to regulate glucose levels. This approach aims to offer patients the potential for long-term remission from Type-2 Diabetes and improve overall health outcomes.

EndoChoice

Series D in 2015
EndoChoice is a medical device company specializing in the development and commercialization of technologies for gastrointestinal (GI) care. Founded in 2008 and headquartered in Alpharetta, Georgia, the company offers a range of products that include single-use devices, diagnostics, infection control products, and endoscopic imaging systems tailored for GI specialists. One of its notable innovations is the Full Spectrum Endoscopy™ System, which features colonoscopes and gastroscopes equipped with multiple imagers, allowing for a wider field of view compared to traditional endoscopes. This technology has demonstrated its efficacy by detecting significantly more polyps during colonoscopy procedures. EndoChoice serves over 2,000 customers in the United States and collaborates with 34 distribution partners globally. The company was recognized by Inc. Magazine as one of the fastest-growing companies in the U.S. for four consecutive years prior to its acquisition by Boston Scientific in 2016.

Corvia

Series D in 2014
Corvia Medical, Inc., established in 2009 and based in Andover, Massachusetts, is a medical device company specializing in structural heart devices for heart failure treatment. Its primary product is the InterAtrial Shunt Device (IASD), a transcatheter device designed to alleviate symptoms and slow the progression of diastolic heart failure, also known as heart failure with preserved ejection fraction (HFpEF). The IASD system reduces elevated left atrial pressure, the primary cause of DHF symptoms, by creating a small opening between the left and right atria, enabling patients to lead healthier lives with reduced heart failure risk.

CartiHeal

Venture Round in 2013
CartiHeal Ltd. is a medical device company based in Kfar Sava, Israel, specializing in the development of innovative solutions for cartilage and bone disorders. Founded in 2009, the company has pioneered a cell-free implant technology known as Agili-C, designed to address focal articular cartilage and osteochondral defects. This off-the-shelf implant promotes the regeneration of true hyaline cartilage and its underlying subchondral bone through a minimally invasive procedure, without the need for cells or growth factors. CartiHeal's Agili-C implant represents a significant advancement in the treatment of cartilage injuries, which can lead to severe pain, disability, and early onset of osteoarthritis if left untreated. By offering a well-tolerated and effective solution, CartiHeal aims to meet a critical need in the field of cartilage repair and regeneration.

Digma Medical

Seed Round in 2013
Digma Medical is a clinical stage medical device company focused on innovative treatments for Type-2 Diabetes and related metabolic disorders, including NASH. Founded in 2013, the company is developing the DiaGone™, a disposable endoscopic device that employs advanced laser technology to target the duodenum, the first section of the small intestine. This device is designed to address insulin resistance, the core issue in these diseases. The Duodenal Glycemic Control™ procedure, which lasts approximately 30 minutes, allows gastroenterologists to utilize the DiaGone™ to enhance the body's natural ability to regulate glucose levels. This approach aims to offer patients the potential for long-term remission from Type-2 Diabetes and improve overall health outcomes.

EndoChoice

Venture Round in 2013
EndoChoice is a medical device company specializing in the development and commercialization of technologies for gastrointestinal (GI) care. Founded in 2008 and headquartered in Alpharetta, Georgia, the company offers a range of products that include single-use devices, diagnostics, infection control products, and endoscopic imaging systems tailored for GI specialists. One of its notable innovations is the Full Spectrum Endoscopy™ System, which features colonoscopes and gastroscopes equipped with multiple imagers, allowing for a wider field of view compared to traditional endoscopes. This technology has demonstrated its efficacy by detecting significantly more polyps during colonoscopy procedures. EndoChoice serves over 2,000 customers in the United States and collaborates with 34 distribution partners globally. The company was recognized by Inc. Magazine as one of the fastest-growing companies in the U.S. for four consecutive years prior to its acquisition by Boston Scientific in 2016.

Valcare

Venture Round in 2012
Valcare, Inc., established in 2012 and headquartered in Irvine, California, specializes in the design and development of medical devices and accessories for minimally invasive treatment of heart valve disease. The company's core technology is a transcatheter platform that functions as a docking station for replacement prostheses and a tool for mitral annulus repair, aiming to improve treatment options and accelerate recovery for patients with mitral and tricuspid regurgitation.

CartiHeal

Venture Round in 2012
CartiHeal Ltd. is a medical device company based in Kfar Sava, Israel, specializing in the development of innovative solutions for cartilage and bone disorders. Founded in 2009, the company has pioneered a cell-free implant technology known as Agili-C, designed to address focal articular cartilage and osteochondral defects. This off-the-shelf implant promotes the regeneration of true hyaline cartilage and its underlying subchondral bone through a minimally invasive procedure, without the need for cells or growth factors. CartiHeal's Agili-C implant represents a significant advancement in the treatment of cartilage injuries, which can lead to severe pain, disability, and early onset of osteoarthritis if left untreated. By offering a well-tolerated and effective solution, CartiHeal aims to meet a critical need in the field of cartilage repair and regeneration.

NLT Spine

Venture Round in 2012
NLT Spine is a clinical stage company focused on developing and marketing innovative products for Minimally Invasive Spinal Surgery (MISS), aimed at treating degenerative spinal conditions. By utilizing non-linear technology, NLT Spine creates instruments and implants specifically designed for lumbar interbody fusion procedures and other surgical treatments of back pain. The company is dedicated to enhancing patient care by transitioning from traditional open surgical methods to more advanced, minimally invasive techniques that improve safety, predictability, and clinical outcomes.

CartiHeal

Series D in 2012
CartiHeal Ltd. is a medical device company based in Kfar Sava, Israel, specializing in the development of innovative solutions for cartilage and bone disorders. Founded in 2009, the company has pioneered a cell-free implant technology known as Agili-C, designed to address focal articular cartilage and osteochondral defects. This off-the-shelf implant promotes the regeneration of true hyaline cartilage and its underlying subchondral bone through a minimally invasive procedure, without the need for cells or growth factors. CartiHeal's Agili-C implant represents a significant advancement in the treatment of cartilage injuries, which can lead to severe pain, disability, and early onset of osteoarthritis if left untreated. By offering a well-tolerated and effective solution, CartiHeal aims to meet a critical need in the field of cartilage repair and regeneration.

Pi-Cardia

Series B in 2011
Pi-Cardia is a medical device start-up focused on developing an innovative low-profile catheter for the treatment of aortic stenosis. The company's proprietary technology utilizes a trans-femoral catheter that incorporates nitinol elements to deliver mechanical impact, creating fractures in calcified heart valves without damaging the surrounding soft tissue. This rapid treatment approach aims to enhance the effective orifice area of the valve, providing a cost-effective and durable solution that eliminates the need for valve replacement. By addressing the challenges associated with aortic stenosis, Pi-Cardia seeks to improve patient outcomes and streamline the treatment process for healthcare providers.

EndoChoice

Venture Round in 2011
EndoChoice is a medical device company specializing in the development and commercialization of technologies for gastrointestinal (GI) care. Founded in 2008 and headquartered in Alpharetta, Georgia, the company offers a range of products that include single-use devices, diagnostics, infection control products, and endoscopic imaging systems tailored for GI specialists. One of its notable innovations is the Full Spectrum Endoscopy™ System, which features colonoscopes and gastroscopes equipped with multiple imagers, allowing for a wider field of view compared to traditional endoscopes. This technology has demonstrated its efficacy by detecting significantly more polyps during colonoscopy procedures. EndoChoice serves over 2,000 customers in the United States and collaborates with 34 distribution partners globally. The company was recognized by Inc. Magazine as one of the fastest-growing companies in the U.S. for four consecutive years prior to its acquisition by Boston Scientific in 2016.

Medical Compression Systems

Post in 2010
Medical Compression Systems (MCS) Ltd. provides solutions for the prevention of deep vein thrombosis (DVT) and venous thromboembolism (VTE). The company’s product pipeline includes ActiveCare+S.F.T., a non-pharmaceutical mechanical solution that provides the prevention of DVT/VTE for in and out of hospital patient settings; and ActiveCare+DTx, which prevents DVT, as well as identifies proximal venous flow obstruction. Its product pipeline also comprises the ActiveCast, a device for bone fracture treatment; and the ActiveCare Vascular, a device used in the outpatient wound care market.

CartiHeal

Series A in 2009
CartiHeal Ltd. is a medical device company based in Kfar Sava, Israel, specializing in the development of innovative solutions for cartilage and bone disorders. Founded in 2009, the company has pioneered a cell-free implant technology known as Agili-C, designed to address focal articular cartilage and osteochondral defects. This off-the-shelf implant promotes the regeneration of true hyaline cartilage and its underlying subchondral bone through a minimally invasive procedure, without the need for cells or growth factors. CartiHeal's Agili-C implant represents a significant advancement in the treatment of cartilage injuries, which can lead to severe pain, disability, and early onset of osteoarthritis if left untreated. By offering a well-tolerated and effective solution, CartiHeal aims to meet a critical need in the field of cartilage repair and regeneration.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.